(Q40591654)

English

Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.

scientific article published on December 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

author name string

S T Lee

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

J H Jang

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

J S Hahn

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

Y W Ko

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

publication date

1 December 2001

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

American Journal of Hematology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

68

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

237-245

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11754412%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

DNA topoisomerase poisons as antitumor drugs

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

Design and analysis of trials of salvage therapy in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.1188

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40591654&oldid=1513625731"